| Evidence for the use of chemotherapy in breast cancer. | |
| | |
MedLine Citation:
|
PMID: 12202979 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Several distinct historical phases mark the evolution of chemotherapy for breast cancer, including the introduction of single agents in the 1960s, the development of cyclophosphamide, methotrexate, and 5-fluorouracil (CMF)-based regimens in the 1970s, the evaluation of the anthracyclines in the 1980s, and the incorporation of the taxanes in the 1990s. The greatest benefit from the use of standard combination chemotherapy occurs in the adjuvant setting, where absolute improvements in overall survival on the order of 10% have been achieved. In contrast, advances have been more modest in the treatment of metastatic disease, and novel agents and regimens are required for further progress. Of the new cytotoxic drugs introduced in the past decade, the taxanes and capecitabine appear to be the most promising, and have demonstrated activity alone and in combination for the treatment of metastatic disease. The introduction of trastuzumab, an antibody directed against the HER2 receptor protein, heralded the birth of targeted molecular therapy against breast cancer. It is clear that in the near future the further evaluation of trastuzumab combinations and the development of additional molecular agents will propel clinical breast cancer research. One of the main challenges of the new era will be identifying and validating predictive factors so that therapy may be individualized based on tumor biology, rather than empirically selected. |
| | |
Authors:
|
Jean-Marc Nabholtz; David Reese; Mary-Ann Lindsay; Alessandro Riva |
Related Documents
:
|
17688969 - Economic evaluation of docetaxel/gemcitabine versus docetaxel as frontline treatment of... 19829059 - Combined anti-angiogenic therapy against vegf and integrin alphavbeta3 in an orthotopic... 11200149 - Irinotecan-based combinations for the adjuvant treatment of stage iii colon cancer. 11996039 - A study of purified montmorillonite intercalated with 5-fluorouracil as drug carrier. 1283849 - The current and future place of vinorelbine in cancer therapy. 19203899 - Phase iii trial of folfox plus bevacizumab or cediranib (azd2171) as first-line treatme... 8564349 - Nosocomial bacterial and fungal meningitis in cancer patients. 21514199 - The role of brachytherapy in the definitive management of prostate cancer. 17467249 - Defining the need for breast cancer radiotherapy in the general population: a criterion... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: International journal of clinical oncology Volume: 7 ISSN: 1341-9625 ISO Abbreviation: Int. J. Clin. Oncol. Publication Date: 2002 Aug |
Date Detail:
|
Created Date: 2002-08-30 Completed Date: 2002-10-09 Revised Date: 2012-12-13 |
Medline Journal Info:
|
Nlm Unique ID: 9616295 Medline TA: Int J Clin Oncol Country: Japan |
Other Details:
|
Languages: eng Pagination: 254-64 Citation Subset: IM |
Affiliation:
|
Cancer Therapy Development Program and Jonsson Comprehensive Cancer Center, University of California, Los Angeles, CA 90095, USA. jean-marc.nabholtz@bcirg.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Breast Neoplasms
/
diagnosis,
drug therapy* Female Humans Tumor Markers, Biological / analysis |
| Chemical | |
Reg. No./Substance:
|
0/Tumor Markers, Biological |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Predictive molecular markers in the adjuvant therapy of breast cancer: state of the art in the year ...
Next Document: The role of aromatase inactivators in the treatment of breast cancer.